Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation
Jessica A Couch1, Gu Zhang2, Joseph C Beyer1
1Development Sciences, Genentech, Inc., South San Francisco, California.
Purpose:
Although agents targeting Delta-like ligand 4 (DLL4) have shown great promise for angiogenesis-based cancer therapy, findings in recent studies have raised serious safety concerns. To further evaluate the potential for therapeutic targeting of the DLL4 pathway, we pursued a novel strategy to reduce toxicities related to DLL4 inhibition by modulating the pharmacokinetic (PK) properties of an anti-DLL4 antibody.
Experimental Design:
The F(ab')2 fragment of anti-DLL4 antibody (anti-DLL4 F(ab')2) was generated and assessed in efficacy and toxicity studies.
Results:
Anti-DLL4 F(ab')2 enables greater control over the extent and duration of DLL4 inhibition, such that intermittent dosing of anti-DLL4 F(ab')2 can maintain significant antitumor activity while markedly mitigating known toxicities associated with continuous pathway inhibition.
Conclusions:
PK modulation has potentially broad implications for development of antibody-based therapeutics. Our safety studies with anti-DLL4 F(ab')2 also provide new evidence reinforcing the notion that the DLL4 pathway is extremely sensitive to pharmacologic perturbation, further underscoring the importance of exercising caution to safely harness this potent pathway in humans.
Insights
Modifying antibody pharmacokinetics (PK) with anti-DLL4 F(ab")2 fragments reduces toxicity while maintaining antitumor activity. This approach offers a safer way to target the Delta-like ligand 4 (DLL4) pathway in cancer therapy.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Delta-like ligand 4 (DLL4) targeting shows promise for angiogenesis-based cancer therapy.
- Recent studies highlight significant safety concerns with DLL4 inhibitors.
- The DLL4 pathway is highly sensitive to pharmacologic modulation.
Purpose of the Study:
- To develop a novel strategy for reducing toxicities associated with DLL4 inhibition.
- To evaluate the therapeutic potential of modulating pharmacokinetic (PK) properties of an anti-DLL4 antibody.
- To assess the efficacy and safety of an anti-DLL4 F(ab')2 fragment.
Main Methods:
- Generation of the F(ab')2 fragment of an anti-DLL4 antibody (anti-DLL4 F(ab')2).
- Assessment of anti-DLL4 F(ab')2 in preclinical efficacy and toxicity studies.
- Evaluation of intermittent dosing strategies for anti-DLL4 F(ab')2.
Main Results:
- Anti-DLL4 F(ab')2 allows for controlled DLL4 inhibition.
- Intermittent dosing of anti-DLL4 F(ab')2 maintained antitumor activity.
- Known toxicities associated with continuous DLL4 pathway inhibition were significantly mitigated.
Conclusions:
- Pharmacokinetic (PK) modulation of anti-DLL4 antibodies offers a promising therapeutic strategy.
- The DLL4 pathway's sensitivity necessitates cautious therapeutic targeting.
- This approach has broad implications for developing safer antibody-based therapeutics.
More Related Videos
09:39Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
07:52Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow